<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01863810</url>
  </required_header>
  <id_info>
    <org_study_id>KW21052_P3</org_study_id>
    <nct_id>NCT01863810</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of KW21052 Compared to Lyrica in the Diabetic Patients With Neuropathic Pain</brief_title>
  <official_title>Randomized, Double-blinded, Double-dummy, Active-controlled, Multi-center Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of KW21052 for 8 Weeks Compared to Pregabalin (Lyrica) in the Diabetic Patients With Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KunWha Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KunWha Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic neuropathy is known to be the most common complication of diabetes, although the
      estimated prevalence is highly variable, ranging from 1.6 to 90%. Also, chronic pain is
      accompanied with sleep disorders, depression, and anxiety, thereby impairing quality of life
      and increasing societal costs. Pregabalin is one of proven and marketed oral medicine to
      manage the chronic neuropathic pain in diabetic patients. This study is designed as a
      randomized controlled trial to demonstrate that the efficacy of KW21052 in pain reduction
      measured by the weekly mean pain score on the numerical pain rating scale (NRS) at the 8th
      week of intervention is inferior to that of Lyrica.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient Reported Outcomes (PRO) using validated questionnaires and patient diaries will be
      assessed for efficacy analysis.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numerical pain rating scale (NRS)</measure>
    <time_frame>After 8 weeks of intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change on on the numerical pain rating scale (NRS)</measure>
    <time_frame>From baseline to 8th week of intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>From baseline to 4th and 8th week of intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Change (CGIC)</measure>
    <time_frame>After 8 weeks of intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improved quality of life (QoL)</measure>
    <time_frame>After 4 and 8 weeks of intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug compliance</measure>
    <time_frame>During 8 weeks of intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Every clinic visit</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">394</enrollment>
  <condition>Diabetic Neuropathy</condition>
  <arm_group>
    <arm_group_label>KW21052</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will be pre-treated with Lyrica 150mg (75mg bid) for titration period of 1 week and then be treated with KW21052 300mg and Placebo of Lyrica for intervention period of 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LYRICA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will be pre-treated with Lyrica 150mg (75mg bid) for titration period of 1 week and then be treated with Lyrica 300mg (150mg bid) and Placebo of KW21052 300mg for intervention period of 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KW21052</intervention_name>
    <description>1 Tablet contains 300mg of pregabalin. Oral, once a day, for 8 weeks.</description>
    <arm_group_label>KW21052</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lyrica</intervention_name>
    <description>1 Capsule contains 150mg of pregabalin. Oral, twice a day, for 8 weeks.</description>
    <arm_group_label>LYRICA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lyrica (low dose)</intervention_name>
    <description>1 Capsule contains 75mg of pregabalin. Oral, twice a day, for 1 week.</description>
    <arm_group_label>KW21052</arm_group_label>
    <arm_group_label>LYRICA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of KW21052</intervention_name>
    <description>Oral,once a day, for 8 weeks</description>
    <arm_group_label>LYRICA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of Lyrica</intervention_name>
    <description>Oral, twice a day, for 8 weeks.</description>
    <arm_group_label>KW21052</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 and 2 diabetic patients

          -  Patients diagnosed with diabetic, distal, symmetrical, and sensorimotor polyneuropathy

          -  40mm and more on VAS

          -  4 and more on NRS

          -  Informed consented patients

        Exclusion Criteria:

          -  Participating in another clinical trial

          -  Pregnancy or lactating

          -  Sensitivity to pregabalin

          -  Significant underlying disease or disorders

          -  Prohibited concomitant medications

          -  Significant laboratory abnormalities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kwang-Kuk Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hae-kwan Eo</last_name>
    <phone>82 2 2047 7789</phone>
    <email>hkeo@kunwha.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Youngrang Lee</last_name>
    <phone>82 70 4335 4759</phone>
    <email>yrlee@symyoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kwang-Kuk Kim, M.D., Ph.D.</last_name>
      <email>kkkim@amc.seoul.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2013</study_first_submitted>
  <study_first_submitted_qc>May 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2013</study_first_posted>
  <last_update_submitted>May 28, 2013</last_update_submitted>
  <last_update_submitted_qc>May 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Neuropathy</keyword>
  <keyword>Neuropathic Pain</keyword>
  <keyword>Pregabalin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

